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Abstract 
In this paper, we examine cross-country differences, in terms of the age distribution 
of symptomatic cases, hospitalizations, intensive care unit (ICU) cases, and 
fatalities due to the novel COVID-19. By calculating conditional probabilities, we 
bridge country-level incidence data gathered from different countries and attribute 
the variability in data to country demographics. We then provide case, 
hospitalization, ICU, and fatality estimates for a comprehensive list of countries 
using the existing data from a variety of countries.  
 
1. Introduction and Background 
The first COVID-19 outbreak took place in the city of Wuhan in the Hubei province of China. 
Despite strict and robust prevention measures taken in the city, the virus has spread the rest of 
the world in a matter of a few weeks. Within three months, the World Health Organization 
(WHO) declared the outbreak a pandemic. While some more significantly than others, the virus 
has taken its toll on all countries with no exception. The global impact of COVID-19 has been 
very profound and probably unprecedented since the Spanish flu (H1N1 influenza circa 1918). 
Due to the novelty of the virus, and the nonexistence of vaccination, health professionals have 
been trying to cope with the pandemic using symptomatic treatment regimes. The rapid spread of 
the virus has caused a record influx of patients at hospitals, pushing the primary care health 
systems to the brink of total collapse. In order to ease the excessive burden on their healthcare 
systems, the governments are seeking out ways to suppress the transmission of the virus.  
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The rapid spread of the virus has even made the calculation of the rate of spread difficult. 
One frequently used way of measuring the spread is by computing the average number of 
secondary cases, or infections, that each case generates. This is known as the R-naught (𝑅𝑅0) of 
the virus. The 𝑅𝑅0’s time and place dependent nature (typically smaller in the South Asian 
countries, depending on measures such as social distancing, isolation, partial or complete 
lockdowns, quarantines by the local authorities) is making modeling the spread of the virus a 
moving target (De Brouwer et al., 2020).  
Even though the literature on COVID-19 is rapidly expanding, there is still a lack of 
consensus among academics and other scientists on the dynamics of the spread. This can perhaps 
be attributed to many reasons, such as the unpreparedness to a pandemic at this level, the lack of 
unified reporting systems due to diversity of health systems across the world, and the novelty of 
the pandemic itself. Many governments are seeking out forming different strategies that involve 
mitigating the spread until a method of prevention or a well-defined, and a successful treatment 
regime is found (Ferguson et al., 2020). The main focus of such mitigation effects is to alleviate 
the burden on healthcare systems by spreading out the diffusion of cases over a more extended 
period of time. While trying to achieve this, governments also face many uncertainties. One such 
uncertainty involves the absence of proven methods to accurately estimate the potential demand 
for healthcare services.  
At the time of this paper's writing, several governments, such as Italy and Spain, already 
had over 100% health services capacity utilization, while others were about to experience a 
similar influx of critical patients. It is clear that governments are in need of better understanding 
the dynamics of the spread for optimal or near-optimal resource allocation decisions. 
Unfortunately, due to the emergency and the gravity of the pandemic and the lack of scantily 
found hard evidence cause such decisions to be made through the seat-of-the-pants approaches.  
Perhaps one of the reasons behind the lack of evidence is that there is no obvious way to 
map reports and studies pertaining to one country into another. Many regional differences make 
this mapping and transfer the learnings and knowledge over to another domain particularly 
difficult. For the case of COVID-19, gender, and age of the patient populations seems to be 
among the key drivers of such differences. Academics are acting swiftly to enrich the medical 
literature by reporting their findings on the virus-related population characteristics, diffusion 
patterns, treatment regimes, case dynamics, hospitalizations, ICU usages, and fatalities.  
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In this paper, we build on the studies and reports that involve age-based clinical fatality 
risks (CFR), infection fatality risks (IFR), hospitalizations, ICU usages, and fatal outcomes. 
Using the latest literature as well as expert opinions, we attempt to combine data from different 
regions in order to estimate and highlight: (i) country-level differences, and (ii) healthcare 
system demands for individual age groups. Specifically, using the data from six different 
countries, we study the spread of the virus for different age groups.   
While it is now known that the virus affects the elderly population more severely than the 
youngers, studies often report inconsistent results. Several underlying reasons may explain these 
inconsistencies. Perhaps one of the most plausible reason is the abundance of undocumented 
cases. In their study, (Li et al., 2020b) highlight that one of the reasons for the rapid spread of the 
virus is due to no documentation. They estimate that around 86% of all infections were 
undocumented. Another study from South Korea suggests similar undocumented case 
percentages at around 55-86% (Kim et al., 2020). News also suggests that even mortality cases 
often go unreported. A recent article in The Economist (Fatal flaws, 2020) highlighted stark 
differences between the number of expected death cases (including those attributed to COVID-
19) and the actual death cases. Their estimation, based on regions’ normal death rates, suggests 
the actual death-toll of the novel COVID-19 being more than double of what is being reported in 
different regions in Italy, Spain, and France. Perhaps this may be one of the reasons for 
conflicting CFR and IFR figures reported in the literature. While some studies suggested an 
estimated case fatality risk of as high as 7.2% (Onder et al., 2020) in Italy, other studies 
suggested a CFR of 3.4% in China (Wilson et al., 2020), 2.3% using the age-adjusted Diamond 
Princess cruise ship data (Russell et al., 2020). More recent works report somewhat lower case 
fatality rates circa 1.4-1.5%% (Guan et al., 2020; Wu et al., 2020), both using data from Wuhan.  
Similar variations also hold for IFR. Studies report IFRs such as 0.5% using the Diamond 
Princess cruise ship data (Russell et al., 2020), 0.94%, and 0.657% using Wuhan data (Famulare, 
2020) and (Verity et al., 2020), respectively. Even though these numbers significantly differ 
from each other, there seems to be (i) convergence to a CFR of 1.5% over time, (ii) CFR/IFR 
ratio appears to hover around 2-3, indicating as much as 40-70% asymptomatic cases of the 
virus.   
One of the apparent reasons behind the differences in reported CFRs is the different 
demographics in different countries. As the virus affects the elderly more than the young, the 
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virus takes a different toll on each country, depending on its age demographics. There may be 
several other reasons, including the fact that the age distribution of the infected population may 
differ from the overall age distribution. Hence, 𝑅𝑅0 may significantly differ across age groups. For 
instance, a recent report indicated that the death-toll for under 60-year-old patients in Turkey is 
as much as four times higher than that of the death-rates in other European countries. As Turkey 
is one of the younger countries, this may be attributed to the demographical differences across 
countries or even mobility differences across the same age groups in different countries. 
In this study, we believe that we make two main contributions to the existing literature. 
First, we investigate the role of age demographics on identified cases, hospitalization, ICU 
usages, and fatalities across different countries. And then, by applying conditional probabilities 
and the existing reports from different countries, we create a country independent conditional 
probability for each group. Second, by coupling expert-formed scenarios for the US, with age-
standardized rates estimated from different countries, we calculate the age breakdown of 
symptomatic cases, hospitalizations, ICU usage, and fatalities.   
In this study, we omit some critical analysis, such as taking into account gender 
differences. In essence, the virus seems to affect males more than females, due to scarcity of 
specific data, along with making some assumptions. For instance, we assume that deaths, 
hospitalizations, and ICU usages are proxy measures for COVID-19 spread. We also assume that 
similar spread patterns apply to each age group across countries—the virus is identical across all 
countries. We also demonstrate some evidence for the acceptability of these assumptions. The 
rest of this paper is organized as follows: in the next section, we describe our method and 
elaborate on the data used. The final section is dedicated to the findings and related discussions.  
2. Method and Dataset 
Many of the existing studies focus on modeling the spread of the COVID-19 have been using a 
few different models such as susceptible-infected-recovered (SIR) and its covariates (mainly 
SEIR: susceptible-exposed-infected-recovered) (Fang et al., 2020; Liu et al., 2020; Peng et al., 
2020; Radulescu and Cavanagh, 2020), Sidarthe model (Giordano et al., 2020). These studies 
often ignore age-dependent variations from one country to another, or are limited to one country, 
or sometimes two (Ferguson et al., 2020). 
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In this study, instead of computing the spread of the virus, we look at the results of 
different scenarios. We base our analyses on expert opinions and the existing data on specific 
countries.  
Expert opinions: Based on the characteristics of the COVID-19, Center for Disease 
Control (CDC) estimated that 2.4 to 21 million Americans would require hospitalization, and a 
death-toll of as much as 480,000 may be expected (Fink, 2020). According to the same 
projection, the death toll could be any figure from 200,000 to as high as 1.7 million. Another 
more recent estimate assuming full social distancing through May (as of April 8, 2020), the 
White House estimated this figure to fall between 30,000 and 126,000 (Institute for Health 
Metrics and Evaluation, 2020b).  
While aggressive quarantines and enforcing/recommending social distancing can change 
the outcome of the burden on healthcare systems, the primary health care capacities are the 
bottleneck for almost all countries. The size of the susceptible population typically depends on 
different 𝑅𝑅0 values. By enforcing/recommending social distancing, governments attempt to 
mitigate the situation and chance this figure (Figure 1).  
 
Figure 1. Different 𝑅𝑅0 values and corresponding estimated percent of susceptible populations.  
The novel coronavirus is often compared and contrasted against seasonal flu. Using CDC 
numbers over the last two flu seasons (2017-2019), we estimate the following table for the 
seasonal flu for comparison purposes.   
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Table 1. The seasonal flu numbers from CDC. 
Seasonal Flu (based on CDC data) US Cases As % of Susceptible Population Per 1M 
Susceptible population (R0=1.3) 134.4M 100.00% 420,000 
Population with symptoms 40M 29.80% 121K 
Medical Visits 15M 11.10% 45.5K 
Hospitalization 0.6M 0.44% 1,823 
Fatality 40K 0.03% 121 
CFR 0.03%   
 
We construct an analogous table to seasonal flu using expert opinions (Fink, 2020; 
Institute for Health Metrics and Evaluation, 2020b). After carefully scanning the existing 
literature, we built Table 2 outlining our analysis. We constructed different scenarios from more 
severe (Scenario 1) to the least severe (Scenario 3) based on the estimates provided by the body 
of experts. We construct this table for the United States. By making use of expert expectations 
based on (Fink, 2020; Murray, 2020) we create a range of possible 𝑅𝑅0 values to estimate the 
percentage of susceptible population. Using the literature, we then estimate upper and lower 
limits for symptomatic cases, reported cases (not all of the symptomatic cases are reported), 
hospitalizations (as a percentage of reported cases), as well as ICU cases (in terms of cases), and 
fatalities. One model (Murray, 2020) makes forecasts of the number of days will be needed, 
while Spain data can be used to calculate this number directly (Ministerio de Sanidad, 2020). 
After age-adjustments, we use data about hospitalizations as well as ICU usages from Spain. 
Assuming 10-15 days of average stay (as suggested in the literature), the data are consistent with 
those reported in (Murray, 2020).  
Similarly, estimating fatalities also is difficult. Case fatality rates depend on a number of 
factors, including:  
(i) The number of tests (and therefore the number of positive cases) conducted each 
individual country. Many countries—excluding countries such as Iceland, where a 
significant portion of the population was tested—conduct selective testing. This 
may involve a selection bias where only the people with severe enough symptoms 
may be tested.  
(ii) The delay between the symptom onsets and the time of deaths.  
(iii) The varying levels of adequacy/inadequacy of the healthcare systems.  
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(iv) The rates of smoking or the prevalence of chronical illnesses. We chose to use 
CFR of 1.5% for the United States for our analysis.  
Table 2. Different COVID-19 spread estimates for the United States (numbers are in millions) 
COVID-19 Scenario 1 Scenario 2 Scenario 3 
Expert 
Opinion 1 
Expert 
Opinion 2 
Susceptible population (overall R0={2.21, 1.8, 1.52} 276.4 240.2 190.8 160-210M - 
The population with symptoms {.503, .35, .204}(C) 138 84 38 - - 
Reported cases (as the ratio of symptomatic 
cases) {.115, .15, .206} 27.6 13 4.2 - - 
Hospitalizations (36%78 of reported cases)(H) 10 4.5 1.5 2.4-21M - 
ICU patients (% of Hospitalizations–7.4%9,10)(I) 0.7 0.34 0.11 - ~0.0811 
Fatalities (D) 0.41 0.19 0.063 0.2-1.7M 0.03-0.12 
CFR {1.512,13} 1.50% 1.50% 1.50%  
 
 
In this study, we use country age distributions (using population pyramids) and data 
involving different countries to create conditional probabilities. The severity of COVID-19 is 
also gender-dependent. However, due to the unavailability of data, we did not take gender into 
account.  
 
1 (Li et al., 2020a): estimates 𝑅𝑅0 value as 2.2 for Wuhan data.  
2 (Shim et al., 2020) estimates 𝑅𝑅0 value as 1.5 for South Korea where the virus is relatively better contained  
3 (Wu et al., 2020) finds a 50% chance of developing symptoms using Wuhan data.  
4 (Day, 2020) suggests that the ratio of asymptomatic cases could be as high as 80%.  
5 (Lachmann et al., 2020) uses South Korean data and similar age corrections and estimate that only around 11% of 
cases are reported in the US. 
6 (Magal and Webb, 2020) uses an estimation interval of 40-60% in their analysis. However, we construct our 
scenarios using similar to the US-based study. 
7 (CDCMMWR, 2020a) CDC estimates also yield a similar number in the US. However, the data has no age 
breakdown and includes some unknown cases. 
8 The rate is estimated as 0.36 using conditional probabilities and age distributions based on Spanish Data 
(Ministerio de Sanidad, 2020) 
9 (Murray, 2020) estimates that around a fifth of hospitalization days will require ICU stays for the US. However, 
they do not provide projections based on the number of hospitalization and ICU cases. Their numbers are in seem 
consistent with Spanish data (Ministerio de Sanidad, 2020).  
10 The crude rate is estimated as 7.4% of total hospitalizations using Spanish Data (Ministerio de Sanidad, 2020). 
However, each case stays in ICU for an average of 15 days (European Society of Anaesthesiology, 2020). (0.074 x 15 
= 1.11) 
11 Assuming a 10-day average duration of stay.  
12 (Guan et al., 0; Wu et al., 2020) indicated a CFR of 1.5%.  
13 (Omer et al., 2020) indicates 0.7% CFR in Germany, such numbers usually come from countries where the spread 
is better contained.  
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We report our findings using the mildest of the three scenarios. We use the following 
notation:  
E: Events, E = {C: Case, A: Age, H: Hospitalization, I: Intensive Unit Care, D: Death) 
𝑃𝑃(𝐶𝐶): The probability of being infected with symptoms. Using the scenario-2 with 
𝑅𝑅0=1.8, we estimate the proportion of the susceptible population as 0.73, with a 35% 
probability of developing symptoms: 𝑃𝑃(𝐶𝐶) = 0.35 × 0.73 
𝑃𝑃(𝑅𝑅): The probability of being a reported case: 𝑃𝑃(𝑅𝑅) = 𝑃𝑃(𝐶𝐶) × .15 
𝑃𝑃(𝐻𝐻): The probability of hospitalization. This number depends on the percentage of 
reported cases, as well as the size of the population with symptoms. Using 0.15 and 36% 
of the rate of hospitalization we use (𝑃𝑃(𝐻𝐻) = 𝑃𝑃(𝐶𝐶) × .11 × .36)  
𝑃𝑃(𝐼𝐼): The probability of needing ICU (𝑃𝑃(𝐼𝐼) = 𝑃𝑃(𝐻𝐻) × 0.074) 
𝑃𝑃(𝐷𝐷): The probability of death for the cases (CFR) (𝑃𝑃(𝐷𝐷) = 𝑃𝑃(𝑅𝑅) × .015) 
 
𝑃𝑃(𝐴𝐴𝑖𝑖): The probability of each age group i for a given country (using the country population 
pyramid) 
𝑃𝑃(𝐶𝐶|𝐴𝐴𝑖𝑖): The probability of being infected with symptoms given age group i  
𝑃𝑃(𝐴𝐴𝑖𝑖|𝐶𝐶): The probability of the age group i, given case.  
We compute other conditional probabilities similarly for events {H, I, D}. We then use 
the conditional probabilities to simulate the mild scenario breakdowns for the United States. By 
using population pyramids and the US data, we replicate the same scenario for each individual 
country and report the results (per 1 million residents). 
𝑃𝑃(𝐶𝐶|𝐴𝐴) = 𝑃𝑃(𝐴𝐴|𝐶𝐶)
𝑃𝑃(𝐴𝐴) 𝑃𝑃(𝐶𝐶)  
A sample table, including some of the probabilities using the reports by the Spanish 
Ministry of Health, is given in Table 3. Using age-corrections via conditional probabilities also 
shows that reported numbers are quite consistent across-countries (Table 4 and Figure 4).  
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Table 3. Probabilities and conditional probabilities for Spain 
Age Group P(A) 
#Conf. 
Cases P(A|C)  #Hosp. P(A|H) 
#IUC 
cases P(A|I) #Deaths P(A|D) 
0-9 9.3% 130 0.6% 35 0.45% 1 0% 0 0.0% 
10-19 10.0% 226 1.1% 20 0.26% 1 0% 1 0.1% 
20-29 10.0% 1,352 6.6% 200 2.6% 10 2% 4 0.5% 
30-39 13.2% 2,386 11.7% 431 5.6% 18 3% 3 0.4% 
40-49 17.0% 3,190 15.6% 778 10.1% 45 8% 9 1.1% 
50-59 14.9% 3,433 16.8% 1,074 13.9% 106 18% 20 2.5% 
60-69 11.1% 3,179 15.6% 1,432 18.6% 162 28% 63 7.8% 
70-79 8.4% 3,304 16.1% 1,858 24.1% 192 34% 164 20.4% 
80+ 6.2% 3,271 16.0% 1,871 24.3% 38 7% 541 67.2% 
 
Table 4. Computing age group probabilities for given cases in (i) Spain, (ii) in the US calculated using 
Spain data14 and (iii) reported by CDC15. While the correlation between (i) and (iii) is .88, the correlation 
between (i) and (ii) is as high as .97.  
Age Group 𝑃𝑃(𝐴𝐴)𝑈𝑈𝑈𝑈 𝑃𝑃(𝐴𝐴)𝑈𝑈𝑆𝑆 𝑃𝑃(𝐴𝐴|𝐶𝐶)𝑈𝑈𝑆𝑆 𝑃𝑃(𝐴𝐴|𝐶𝐶)𝑈𝑈𝑈𝑈 from Spain data 𝑃𝑃(𝐴𝐴|𝐶𝐶)𝑈𝑈𝑈𝑈 reported 
0-9 12.1% 9.3% 0.6% 0.9% 2.5% 
10-19 12.9% 10.0% 1.1% 1.6% 2.5% 
20-29 14.0% 10.0% 6.6% 10.5% 11.5% 
30-39 13.4% 13.2% 11.7% 13.3% 11.5% 
40-49 12.2% 17.0% 15.6% 12.7% 14.5% 
50-59 12.9% 14.9% 16.8% 16.4% 17.5% 
60-69 11.5% 11.1% 15.5% 18.1% 17.1% 
70-79 7.0% 8.4% 16.1% 15.1% 12.6% 
80+ 3.9% 6.2% 16.0% 11.4% 10.2% 
 
We then use country demographics, CDC estimations for the US, and data sets available 
(Table) to compute age-adjusted probabilities and number of cases for each of the events 
(Susceptible, Case with symptoms, Hospitalization, IUC case, and Deaths) for countries with a 
 
14 (Ministerio de Sanidad, 2020) 
15 (CDCMMWR, 2020b) 
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population of more than 10 million people. We report all numbers per 1-million for ease of 
comparison.  
Table 5. Datasets used in this study 
Country 
South 
Korea1 Spain2 US3 China4 Italy5 
Number of cases 6,284 20,471 2,449 44,669 ~34,000 
Number of hospitalizations - 7,699 - - - 
Number of ICU cases - 573 - - - 
Number of fatalities 42 805 44 805 1,625 
1.(Shim et al., 2020)  
2.(Ministerio de Sanidad, 2020) 
3.(Shim et al., 2020)  
4.(Verity et al., 2020) 
5.(Onder et al., 2020) 
 
Studies report different case- and death-related age-breakdowns for a variety of countries. 
We observed that taking conditional probabilities—based on population age distributions in 
individual countries—into account, can help mitigate the variability in the reported results 
(Figure 2).  
 
Figure 2. Age breakdown patterns of cases with (left) and without (right) taking country population 
pyramids (in terms of conditional probabilities) into account.  
Figure 3 also highlights the age differences for different events. ICU beds and invasive 
ventilators are in short supply, and some health systems prioritize younger patients over the older 
ones in order to increase the chances of survival. While debated, the figure also demonstrates 
such preferences.    
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Figure 3. Age pyramids for cases, hospitalization, ICU uses, and fatalities for Spain. 
Unfortunately, the only source of data that explicitly provided the age breakdowns of 
hospitalization and ICU cases (P(A|H), and P(A|I)) we could found was Spain (Ministerio de 
Sanidad, 2020). After comparing the estimated P(H) and P(I)s from Spain data and the data from 
the Institute for Health Metrics and Evaluation (2020), we concluded the numbers are consistent 
and decided to use age breakdowns from the Spanish dataset. 
Table 6. Conditional probabilities for hospitalization and ICU using Spain data.  
Age Group Hospitalized P(A|H) ICU P(A|I) 
0-9 35 0.5% 1 0.2% 
10-19 20 0.3% 1 0.2% 
20-29 200 2.6% 10 1.7% 
30-39 431 5.6% 18 3.1% 
40-49 778 10.1% 45 7.9% 
50-59 1,074 13.9% 106 18.5% 
60-69 1,432 18.6% 162 28.3% 
70-79 1,858 24.1% 192 33.5% 
80+ 1,871 24.3% 38 6.6% 
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3. Results and Discussion 
In this paper, we focus on age-dependent breakdowns of cases, hospitalizations, ICU usages, and 
fatalities (events) using a range of scenarios. We construct these scenarios by using expert views 
and existing reports in the literature and based on the US data. We then use conditional 
probabilities to compute age-standardized breakdowns for the events for all individual countries.  
Our results propose a few important implications. Firstly, the results highlight the effect 
of demographical differences across countries on COVID-19 spread. They suggest that, provided 
everything else remains the same, the death toll difference due to age demographics could be as 
much as 20 times (Niger vs. Japan, Figure 4).  
Secondly, our results have the potential to help decision-makers to accommodate age-
specific aspects of the spread. Creating different age-based isolation strategies, depending on the 
age-demographics of individual countries may be considered.  
Also, our study attempts to combine several parameters calculated or taken from different 
academic papers, reports, or data sources together in creating a range of scenarios. While this 
approach provides a somewhat holistic view of the phenomenon, it also omits other country-level 
differences such as social isolation policies, prevention strategies, the effectiveness of the 
individual health-care systems. Our final table (Appendix-1) must be interpreted as a comparison 
tool for different countries’ exposure to the virus.  
 
Figure 4. Age-dependent event estimations for the US, the country with the youngest population in the 
world (Niger), and with the oldest (Japan).  
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Appendix 1  
Table 7. Scenario-2 based event breakdowns for individual countries. 
Population 
(K) 
Cases per 
1M 
Hosp. per 
1M 
ICU per 
1M 
Deaths 
per 1M Country 
10,196 275,770 16,717 1,218 854 Portugal 
83,783 275,671 16,521 1,194 852 Germany 
60,461 275,463 16,903 1,223 902 Italy 
10,423 273,517 16,472 1,173 879 Greece 
8,655 272,148 15,554 1,130 720 Switzerland 
6,949 271,055 16,053 1,216 706 Bulgaria 
126,475 271,042 17,430 1,256 1,037 Japan 
9,660 270,439 15,464 1,160 665 Hungary 
5,542 270,389 16,135 1,195 784 Finland 
17,136 269,922 15,626 1,169 705 Netherlands 
46,733 269,495 15,673 1,117 772 Spain 
51,270 269,133 14,500 1,102 556 Republic of Korea 
19,236 268,786 15,330 1,133 677 Romania 
37,847 267,820 15,109 1,113 656 Poland 
11,589 267,496 15,314 1,104 736 Belgium 
5,792 266,784 15,340 1,144 694 Denmark 
10,708 265,466 15,251 1,153 642 Czechia 
10,099 264,504 15,248 1,108 729 Sweden 
67,886 264,035 14,909 1,078 694 United Kingdom 
43,734 263,634 14,445 1,065 598 Ukraine 
5,421 261,559 14,405 1,060 619 Norway 
11,326 260,576 13,965 1,038 562 Cuba 
9,449 256,685 13,641 1,004 548 Belarus 
329,064 255,500 13,797 1,021 575 US 
4,822 254,069 13,778 1,022 576 New Zealand 
25,498 253,440 13,696 993 590 Australia 
145,935 253,217 13,567 997 551 Russian Federation 
3,474 244,333 12,945 912 586 Uruguay 
4,938 242,002 12,670 941 493 Ireland 
19,116 234,534 11,579 853 429 Chile 
1,439,324 227,809 10,805 875 326 China 
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Population 
(K) 
Cases per 
1M 
Hosp. per 
1M 
ICU per 
1M 
Deaths 
per 1M Country 
45,197 213,004 10,468 759 400 Argentina 
8,655 211,875 10,745 771 438 Israel 
21,413 211,258 10,060 822 304 Sri Lanka 
212,560 207,735 9,592 722 318 Brazil 
50,883 198,163 9,060 679 301 Colombia 
7,794,799 197,313 9,131 688 304 World 
11,819 196,661 8,884 680 281 Tunisia 
84,339 195,387 8,928 677 290 Turkey 
32,972 191,468 8,717 649 290 Peru 
97,338 190,509 8,391 608 284 Viet Nam 
18,776 181,352 8,042 604 258 Kazakhstan 
28,437 180,853 8,072 628 247 Venezuela (Bolivarian Republic of) 
128,933 177,978 7,887 589 256 Mexico 
10,847 174,998 7,815 574 263 Dominica 
10,139 173,391 7,261 557 214 Azerbaijan 
17,643 173,165 7,726 571 257 Ecuador 
36,910 172,690 7,503 604 214 Morocco 
32,365 168,392 7,211 575 205 Malaysia 
11,674 163,184 7,436 533 267 Bolivia 
83,993 161,603 6,787 541 189 Iran (Islamic Republic of) 
43,852 159,997 6,934 521 217 Algeria 
7,132 155,116 6,797 516 213 Paraguay 
1,380,004 154,638 6,475 529 176 India 
273,523 154,124 6,343 531 165 Indonesia 
164,690 142,614 5,915 448 177 Bangladesh 
109,581 136,985 5,625 457 152 Philippines 
29,138 133,698 5,539 465 145 Nepal 
59,308 132,704 5,360 455 135 South Africa 
6,031 129,106 5,120 398 143 Turkmenistan 
102,335 129,065 5,306 440 140 Egypt 
33,470 128,528 5,038 401 135 Uzbekistan 
17,500 125,473 5,083 400 141 Syrian Arab Republic 
220,892 112,174 4,521 370 119 Pakistan 
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Population 
(K) 
Cases per 
1M 
Hosp. per 
1M 
ICU per 
1M 
Deaths 
per 1M Country 
10,205 108,890 4,301 345 114 Jordan 
34,815 102,129 3,777 317 91 Saudi Arabia 
43,849 93,224 3,681 308 93 Sudan 
114,964 88,752 3,545 291 93 Ethiopia 
40,223 88,523 3,410 280 87 Iraq 
40,223 88,523 3,410 280 87 Iraq 
11,195 85,682 3,366 285 84 South Sudan 
5,101 85,658 3,307 278 82 State of Palestine 
27,692 82,226 3,138 265 77 Madagascar 
31,073 79,587 2,934 280 63 Ghana 
16,745 77,735 2,989 261 71 Senegal 
89,561 76,412 2,970 255 72 Democratic Republic of the Congo 
29,825 74,766 2,840 250 67 Yemen 
31,255 71,548 2,752 239 66 Mozambique 
15,893 70,564 2,714 242 63 Somalia 
26,378 68,960 2,558 243 55 Côte d'Ivoire 
26,545 68,088 2,540 232 57 Cameroon 
59,734 66,731 2,484 229 55 United Republic of Tanzania 
38,928 66,159 2,469 227 55 Afghanistan 
53,771 66,064 2,407 219 53 Kenya 
206,139 60,712 2,193 228 43 Nigeria 
20,903 60,006 2,200 209 47 Burkina Faso 
20,249 59,879 2,230 207 49 Mali 
24,207 59,262 2,215 215 47 Niger 
 
